Department of Psychiatry, University of Arizona, Tucson, Arizona.
Co-first authors.
J Clin Sleep Med. 2021 May 1;17(5):1025-1030. doi: 10.5664/jcsm.9096.
Z-drugs (eszopiclone, zolpidem, and zaleplon) are commonly used for insomnia but are also associated with suicide risk. However, it is unclear if this association is unique to Z-drugs. Therefore, the present study estimated the associations between multiple prescription insomnia medications and suicidal thoughts and behaviors.
Data were acquired from the National Survey on Drug Use and Health for 2015-2018 and the National Health and Nutrition Examination Survey for 2005-2018. Samples were balanced on sociodemographic and mental health covariates using inverse probability of treatment weighting. Associations of Z-drugs, trazodone, and sedative benzodiazepines (temazepam, triazolam, flurazepam) with suicidal ideation, planning, and attempts were estimated using binomial logistic regression.
In the National Survey on Drug Use and Health, Z-drugs were associated with suicidal ideation (odds ratio [OR], 1.32; 95% confidence interval [CI], 1.14-1.54]), suicide planning (OR, 1.44; 95% CI, 1.19-1.75), and suicide attempts (OR, 1.45; 95% CI, 1.13-1.86) after adjusting for age, sex, race/ethnicity, income, depression, illicit substance use, and the 6-item Kessler Psychological Distress Scale and World Health Organization Disability Assessment Schedule II scores. When analyses accounted for the same factors, sedative benzodiazepines were associated with suicide attempts (OR, 1.76; 95% CI, 1.06-2.87) but not suicidal ideation (OR, 1.37; 95% CI, 0.99-1.88) or suicide planning (OR, 1.39; 95% CI, 0.97-2.00). In the National Health and Nutrition Examination Survey, Z-drugs were associated with suicidal ideation (OR, 2.44; 95% CI, 1.41-4.22), as was trazodone (OR, 2.33; 95% CI, 1.45-3.75), after analyses adjusted for age, sex, race/ethnicity, and exposure to various psychotropic medications.
Multiple classes of prescription insomnia medications are associated with suicidal thinking and behaviors, even after analyses adjusted for measures of mental health.
Z 类药物(右佐匹克隆、唑吡坦和扎来普隆)常用于治疗失眠,但也与自杀风险相关。然而,目前尚不清楚这种关联是否仅存在于 Z 类药物中。因此,本研究旨在评估多种处方失眠药物与自杀意念和行为之间的关联。
本研究数据来自 2015-2018 年的全国药物使用和健康调查以及 2005-2018 年的全国健康和营养调查。使用逆概率治疗加权法,对社会人口统计学和心理健康协变量进行样本平衡。使用二项逻辑回归估计 Z 类药物、曲唑酮和镇静苯二氮䓬类药物(替马西泮、三唑仑、氟西泮)与自杀意念、自杀计划和自杀企图之间的关联。
在全国药物使用和健康调查中,调整年龄、性别、种族/民族、收入、抑郁、非法药物使用以及 6 项 Kessler 心理困扰量表和世界卫生组织残疾评估量表 II 评分后,Z 类药物与自杀意念(优势比 [OR],1.32;95%置信区间 [CI],1.14-1.54)、自杀计划(OR,1.44;95% CI,1.19-1.75)和自杀企图(OR,1.45;95% CI,1.13-1.86)相关。当分析考虑到相同的因素时,镇静苯二氮䓬类药物与自杀企图(OR,1.76;95% CI,1.06-2.87)相关,但与自杀意念(OR,1.37;95% CI,0.99-1.88)或自杀计划(OR,1.39;95% CI,0.97-2.00)无关。在全国健康和营养调查中,调整年龄、性别、种族/民族和接触各种精神药物后,Z 类药物(OR,2.44;95% CI,1.41-4.22)和曲唑酮(OR,2.33;95% CI,1.45-3.75)与自杀意念相关。
即使在调整心理健康测量后,多种类别的处方失眠药物与自杀意念和行为相关。